Nesfatin-1 in advanced lung cancer patients with weight loss

• Published in: Regulatory peptides Vol. 181; pp. 1 - 3
• Main Authors: Çetinkaya, Hakkı, Karagöz, Bülent, Bilgi, Oğuz, Özgün, Alpaslan, Tunçel, Tolga, Emirzeoğlu, Levent, Top, Cihan, Kandemir, Emin Gökhan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 10.02.2013
• Subjects: Aged; Aged, 80 and over; Body Mass Index; Cachexia; Cachexia - blood; Cachexia - complications; Cachexia - genetics; Cachexia - pathology; Calcium-Binding Proteins - blood; Calcium-Binding Proteins - genetics; Carcinoma, Non-Small-Cell Lung - blood; Carcinoma, Non-Small-Cell Lung - complications; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Case-Control Studies; DNA-Binding Proteins - blood; DNA-Binding Proteins - genetics; Female; Gene Expression Regulation, Neoplastic; Humans; Lung cancer; Lung Neoplasms - blood; Lung Neoplasms - complications; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Male; Middle Aged; Neoplasm Staging; Nerve Tissue Proteins - blood; Nerve Tissue Proteins - genetics; Nesfatin; Weight Loss; Cachexia; Nesfatin; Lung cancer; Weight loss
• ISSN: 0167-0115; 1873-1686
• DOI: 10.1016/j.regpep.2012.11.005

The cachexia occurs frequently in lung cancer patients. Among appetite regulatory peptides, alteration of expressions of leptin and ghrelin is demonstrated in cachectic cancer patients, but nesfatin-1 has not been yet studied in cancer. We investigated serum nesfatin-1 level in advanced lung cancer patients. Forty-one lung cancer patients and 24 healthy subjects were included to the study. Nesfatin-1 serum levels were analyzed by ELISA kit. Serum nesfatin-1 levels were lower in lung cancer patients than in healthy subjects (0.52±0.19ng/ml vs 0.75±0.23ng/ml; p<0.001). In lung cancer patients with weight loss, nesfatin-1 levels were decreased compared to the patients without weight loss (0.44±0.16ng/ml vs 0.63±0.18ng/ml; p<0.001). Whereas, there were no any difference between patients without weight loss and control subjects (0.63±0.18ng/ml vs 0.75±0.23ng/ml; p:0.129) or between SCLC and NSCLC patients (0.53±0.18ng/ml vs 0.52±0.20ng/ml; p:0.458). No significant correlation was found between serum nesfatin-1 values and BMI. In conclusion, loss of fat mass may decrease serum nesfatin-1 level in lung cancer patients with weight loss. The future studies which explore biological significance of low serum nesfatin-1 level in cancer are needed. ► Serum nesfatin-1 levels were lower in lung cancer patients. ► In lung cancer patients with weight loss, nesfatin-1 levels were decreased. ► No significant correlation was found between serum nesfatin-1 and BMI.